Current and Future Oral Systemic Therapies for Psoriasis

Dermatologic Clinics

Volumn 33, Issue 1, 2015, Pages 91-109

  Kelly, John B ^a   Foley, Peter ^b   Strober, Bruce E ^a,c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PROBITY MEDICAL RESEARCH   (Canada)

Author keywords

Acitretin; Apremilast; Cyclosporine; Methotrexate; Mycophenolate mofetil; Psoriasis; Tofacitinib

Indexed keywords

ANTIPSORIASIS AGENT; APREMILAST; CYCLOSPORIN; ESTER DERIVATIVE; ETRETIN; FUMARIC ACID DERIVATIVE; FUMARIC ACID ESTER DERIVATIVE; HYDROXYUREA; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SALAZOSULFAPYRIDINE; TIOGUANINE; TOFACITINIB; UNCLASSIFIED DRUG; ANTIMETABOLITE; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; KERATOLYTIC AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; THALIDOMIDE;

ALOPECIA; ANOREXIA; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CHRONIC DRUG ADMINISTRATION; DIARRHEA; DISEASE CONTROL; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; EOSINOPHILIA; ERYTHEMA; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; INFECTION; LEUKOPENIA; LIVER INJURY; LIVER TOXICITY; MAINTENANCE THERAPY; MOUTH ULCER; MYALGIA; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PATIENT ASSESSMENT; PATIENT MONITORING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PUSTULE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SHORT COURSE THERAPY; SYSTEMIC THERAPY; TREMOR; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; XEROSIS; ANALOGS AND DERIVATIVES;

ACITRETIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES; CYCLOSPORINE; FUMARATES; HUMANS; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KERATOLYTIC AGENTS; METHOTREXATE; MYCOPHENOLIC ACID; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES; SULFASALAZINE; THALIDOMIDE; THIOGUANINE;

EID: 84911496381     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.09.008     Document Type: Review

References (75)

1. Menter A., Korman N.J., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. JAm Acad Dermatol 2009, 61(3):451-485.
2. Mehta N.N., Azfar R.S., Shin D.B., et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 2010, 31(8):1000-1006.
3. Miller I.M., Ellervik C., Yazdanyar S., et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. JAm Acad Dermatol 2013, 69(6):1014-1024.
4. Hugh J., Van voorhees A.S., Nijhawan R.I., et al. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 2014, 70(1):168-177.
5. Strober B.E., Siu K., Menon K. Conventional systemic agents for psoriasis. A systematic review. JRheumatol 2006, 33(7):1442-1446.
6. Smolen J.S., Van der heijde D., Machold K.P., et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014, 73(1):3-5.
7. Chan E.S., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002, 4(4):266-273.
8. Montesinos M.C., Desai A., Delano D., et al. Adenosine A2A or A3 receptors are required for inhibition ofinflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003, 48(1):240-247.
9. Dogra S., Krishna V., Kanwar A.J. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol 2012, 37(7):729-734.
10. Chládek J., Martínková J., Simková M., et al. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998, 53(6):437-444.
11. Pichlmeier U., Heuer K. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Arthritis Rheum 2013, 65(Suppl 10):1355. [abstract].
12. Schiff M.H., Simon L.S., Dave K.J., et al. Self-administered methotrexate using a medi-jet auto-injector improves bioavailability compared with oral methotrexate in adults with rheumatoid arthritis. Ann Rheum Dis 2013, 72(Suppl 3):249.
13. Hamilton R.A., Kremer J.M. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997, 36(1):86-90.
14. van Roon E.N., van de Laar M.A. Methotrexate bioavailability. Clin Exp Rheumatol 2010, 28(5 Suppl 61):S27-S32.
15. Braun J., Kästner P., Flaxenberg P., et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008, 58(1):73-81.
16. Islam M.S., Haq S.A., Islam M.N., et al. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Med J 2013, 22(3):483-488.
17. Hameed B., Jones H. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. Int J Rheum Dis 2010, 13(4):e83-e84.
18. Rutkowska-Sak L., Rell-Bakalarska M., Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Rheumatolgia 2009, 47(4):207-211.
19. Whittle S.L., Hughes R.A. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004, 43(3):267-271.
20. Morgan S.L., Oster R.A., Lee J.Y., et al. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 2004, 50(10):3104-3111.
21. Saurat J.H., Stingl G., Dubertret L., et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008, 158(3):558-566.
22. Reich K., Langley R.G., Papp K.A., et al. A52-week trial comparing briakinumab with methotrexate in patients with psoriasis. NEngl J Med 2011, 365(17):1586-1596.
23. Barker J., Hoffmann M., Wozel G., et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011, 165(5):1109-1117.
24. Hébert H.L., Ali F.R., Bowes J., et al. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 2012, 166(3):474-482.
25. Strober B.E. Methotrexate-induced liver toxicity: replacing the liver biopsy. JAMA Dermatol 2014, 150(8):862-863. [Epub ahead of print].
26. Barker J., Horn E.J., Lebwohl M., et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. JEur Acad Dermatol Venereol 2011, 25(7):758-764.
27. Van der voort E.A., Koehler E.M., Dowlatshahi E.A., et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. JAm Acad Dermatol 2014, 70(3):517-524.
28. Rosenberg P., Urwitz H., Johannesson A., et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. JHepatol 2007, 46(6):1111-1118.
29. Heydendael V.M., Spuls P.I., Opmeer B.C., et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. NEngl J Med 2003, 349(7):658-665.
30. Foley P.A., Quirk C., Sullivan J.R., et al. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. JEur Acad Dermatol Venereol 2010, 24(10):1135-1143.
31. Salvarini C., Boiardi L., Macchioni P., et al. Multidisciplinary focus on cyclosporin A. JRheumatol 2009, 36(Suppl 83):52-55.
32. Amor K.T., Ryan C., Menter A. The use of cyclosporine in dermatology: part I. JAm Acad Dermatol 2010, 63(6):925-946.
33. Buchbinder R., Barber M., Heuzenroeder L., et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008, 59(6):794-799.
34. Griffiths C.E., Dubertret L., Ellis C.N., et al. Ciclosporin in psoriasis clinical practice: an International Consensus Statement. Br J Dermatol 2004, 150(Suppl 67):11-23.
35. Flytström I., Stenberg B., Svensson A., et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008, 158(1):116-121.
36. Ho S.G., Yeung C.K., Chan H.H. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life. Clin Exp Dermatol 2010, 35(7):717-722.
37. Akhyani M., Chams-davatchi C., Hemami M.R., et al. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. JEur Acad Dermatol Venereol 2010, 24(12):1447-1451.
38. Radmanesh M., Rafiei B., Moosavi Z.B., et al. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial. Int J Dermatol 2011, 50(10):1291-1293.
39. Baranauskaite A., Raffayová H., Kungurov N.V., et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012, 71(4):541-548.
40. Ranjan N., Sharma N.L., Shanker V., et al. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. JDermatolog Treat 2007, 18(5):295-300.
41. Mahbub M.S., Khondker L., Khan S.I., et al. Comparative efficacy of hydroxyurea and methotrexate in treating psoriasis. Mymensingh Med J 2013, 22(1):116-130.
42. Fallah Arani S., Neumann H., Hop W.C., et al. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol 2011, 164(4):855-861.
43. Ellis C.N., Fradin M.S., Messana J.M., et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. NEngl J Med 1991, 324(5):277-284.
44. Reitamo S., Spuls P., Sassolas B., et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001, 145(3):438-445.
45. Yoon H.S., Youn J.I. Acomparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. JDermatolog Treat 2007, 18(5):286-290.
46. Pedraz J., Daudén E., Delgado-jiménez Y., et al. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin. JEur Acad Dermatol Venereol 2006, 20(6):702-706.
47. Beissert S., Pauser S., Sticherling M., et al. Acomparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis. Dermatology 2009, 219(2):126-132.
48. Tauscher A.E., Fleischer A.B., Phelps K.C., et al. Psoriasis and pregnancy. JCutan Med Surg 2002, 6(6):561-570.
49. Baroz B., Hackman R., Einarson T., et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001, 71(8):1051-1055.
50. Dogra S., Yadav S. Acitretin in psoriasis: an evolving scenario. Int J Dermatol 2014, 53(5):525-538.
51. Gollnick H., Bauer R., Brindley C., et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. JAm Acad Dermatol 1988, 19(3):458-468.
52. Berbis P., Geiger J.M., Vaisse C., et al. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica 1989, 178(2):88-92.
53. Van de kerkhof P.C., Cambazard F., Hutchinson P.E., et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998, 138(1):84-89.
54. Lassus A., Geiger J.M. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988, 119(6):755-759.
55. Papp K.A., Menter A., Strober B., et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012, 167(3):668-677.
56. A phase 3, multi site, randomized, double blind, placebo controlled study of the efficacy and safety comparing CP-690,550 and etanercept in subjects with moderate to severe chronic plaque psoriasis. ClinicalTrials.gov. Available at: . Accessed May 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01241591.
57. A study to evaluate the effects and safety of treatment, treatment withdrawal, followed by re-treatment with CP-690,550 in subjects with moderate to severe chronic plaque psoriasis. ClinicalTrials.gov. Available at: . Accessed May 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01186744.
58. Strober B., Buonanno M., Clark J.D., et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013, 169(5):992-999.
59. Kavanaugh A., Mease P.J., Gomez-reino J.J., et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014, 73(6):1020-1026.
60. Papp K., Cather J.C., Rosoph L., et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012, 380(9843):738-746.
61. Gottlieb A.B., Strober B., Krueger J.G., et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008, 24(5):1529-1538.
62. Paul C, Cather J, Gooderham M, etal. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2). Poster presented at 72nd AAD Annual Meeting. Denver, CO. Available at: . Accessed April 30, 2014. http://www.aad.org/Posters/Documents/AM2014/Poster/8412/8412.
63. Reich K, Papp K, Leonardi C, etal. Long-term safetyand tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a Phase III, Randomized, Controlled Trial (ESTEEM 1). Poster presented at 72nd AAD Annual Meeting. Denver, CO. Available at: . Accessed April 30, 2014. http://www.aad.org/Posters/Documents/AM2014/Poster/8296/8296.
64. Otezla [Package Insert]. NJ: Celgene Corporation, Summit; 2014.
65. Fallah arani S., Waalboer Spuij R., Nijsten T., et al. Enteric-coated mycophenolate sodium in psoriasis vulgaris: an open pilot study. JDermatolog Treat 2014, 25(1):46-49.
66. Zhou Y., Rosenthal D., Dutz J., et al. Mycophenolate mofetil (CellCept) for psoriasis: a two-center, prospective, open-label clinical trial. JCutan Med Surg 2003, 7(3):193-197.
67. Kaltenborn A., Schrem H. Mycophenolate mofetil in liver transplantation: a review. Ann Transplant 2013, 18:685-696.
68. Kaltwasser J.P., Nash P., Gladman D., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004, 50(6):1939-1950.
69. Wain E.M., Darling M.I., Pleass R.D., et al. Treatment ofsevere, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol 2010, 162(2):427-434.
70. Heelan K., Markham T. Fumaric acid esters as a suitable first-line treatment for severe psoriasis: an Irish experience. Clin Exp Dermatol 2012, 37(7):793-795.
71. Zackheim H.S., Glogau R.G., Fisher D.A., et al. 6-Thioguanine treatment of psoriasis: experience in 81 patients. JAm Acad Dermatol 1994, 30(3):452-458.
72. Zackheim H.S., Maibach H.I. Treatment of psoriasis with 6-thioguanine. Australas J Dermatol 1988, 29(3):163-167.
73. Silvis N.G., Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol 1999, 135(4):433-437.
74. Gupta A.K., Ellis C.N., Siegel M.T., et al. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 1990, 126(4):487-493.
75. El-Mofty M., El-Darouti M., Fawzy M., et al. Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative. JDermatolog Treat 2011, 22(1):31-37. [serial online], Available from: Academic Search Premier, Ipswich, MA. Accessed April 30, 2014.